Valid for Submission
C94.20 is a billable diagnosis code used to specify a medical diagnosis of acute megakaryoblastic leukemia not having achieved remission. The code C94.20 is valid during the fiscal year 2022 from October 01, 2021 through September 30, 2022 for the submission of HIPAA-covered transactions.
The ICD-10-CM code C94.20 might also be used to specify conditions or terms like acute megakaryoblastic leukemia, megakaryoblastic acute myeloid leukemia with t or megakaryocytic leukemia.
Tabular List of Diseases and Injuries
The Tabular List of Diseases and Injuries is a list of ICD-10 codes, organized "head to toe" into chapters and sections with coding notes and guidance for inclusions, exclusions, descriptions and more. The following references are applicable to the code C94.20:
Inclusion TermsInclusion Terms
These terms are the conditions for which that code is to be used. The terms may be synonyms of the code title, or, in the case of "other specified" codes, the terms are a list of the various conditions assigned to that code. The inclusion terms are not necessarily exhaustive. Additional terms found only in the Alphabetic Index may also be assigned to a code.
- Acute megakaryoblastic leukemia with failed remission
- Acute megakaryoblastic leukemia NOS
The following clinical terms are approximate synonyms or lay terms that might be used to identify the correct diagnosis code:
- Acute megakaryoblastic leukemia
- Megakaryoblastic acute myeloid leukemia with t
- Megakaryocytic leukemia
Diagnostic Related Groups - MS-DRG Mapping
|MS-DRG||MS-DRG Title||MCD||Relative Weight|
|820||LYMPHOMA AND LEUKEMIA WITH MAJOR O.R. PROCEDURES WITH MCC||17||5.6873|
|821||LYMPHOMA AND LEUKEMIA WITH MAJOR O.R. PROCEDURES WITH CC||17||2.1551|
|822||LYMPHOMA AND LEUKEMIA WITH MAJOR O.R. PROCEDURES WITHOUT CC/MCC||17||1.2516|
The relative weight of a diagnostic related group determines the reimbursement rate based on the severity of a patient's illness and the associated cost of care during hospitalization.
Convert C94.20 to ICD-9 Code
The General Equivalency Mapping (GEM) crosswalk indicates an approximate mapping between the ICD-10 code C94.20 its ICD-9 equivalent. The approximate mapping means there is not an exact match between the ICD-10 code and the ICD-9 code and the mapped code is not a precise representation of the original code.
Information for Patients
Acute Myeloid Leukemia
What is leukemia?
Leukemia is a term for cancers of the blood cells. Leukemia starts in blood-forming tissues such as the bone marrow. Your bone marrow makes the cells which will develop into white blood cells, red blood cells, and platelets. Each type of cell has a different job:
- White blood cells help your body fight infection
- Red blood cells deliver oxygen from your lungs to your tissues and organs
- Platelets help form clots to stop bleeding
When you have leukemia, your bone marrow makes large numbers of abnormal cells. This problem most often happens with white blood cells. These abnormal cells build up in your bone marrow and blood. They crowd out the healthy blood cells and make it hard for your cells and blood to do their work.
What is acute myeloid leukemia (AML)?
Acute myeloid leukemia (AML) is a type of acute leukemia. "Acute" means that the leukemia usually gets worse quickly if it's not treated. In AML, the bone marrow makes abnormal myeloblasts (a type of white blood cell), red blood cells, or platelets. When the abnormal cells crowd out the healthy cells, it can lead to infection, anemia, and easy bleeding. The abnormal cells can also spread outside the blood to other parts of the body.
There are several different subtypes of AML. The subtypes are based on how developed the cancer cells are when you get your diagnosis and how different they are from normal cells.
What causes acute myeloid leukemia (AML)?
AML happens when there are changes in the genetic material (DNA) in bone marrow cells. The cause of these genetic changes is unknown. However, there are certain factors that raise your risk of AML.
Who is at risk for acute myeloid leukemia (AML)?
The factors that raise your risk of AML include
- Being male
- Smoking, especially after age 60
- Having had chemotherapy or radiation therapy
- Treatment for acute lymphoblastic leukemia (ALL) as a child
- Exposure to the chemical benzene
- A history of another blood disorder such as myelodysplastic syndrome
What are the symptoms of acute myeloid leukemia (AML)?
The signs and symptoms of AML include
- Shortness of breath
- Easy bruising or bleeding
- Petechiae, which are tiny red dots under the skin. They are caused by bleeding.
- Weakness or feeling tired
- Weight loss or loss of appetite
- Bone or joint pain, if the abnormal cells build up near or inside the bones
How is acute myeloid leukemia (AML) diagnosed?
Your health care provider may use many tools to diagnose AML and figure out which subtype you have:
- A physical exam
- A medical history
- Blood tests, such as a complete blood count (CBC) and blood smear
- Bone marrow tests. There are two main types - bone marrow aspiration and bone marrow biopsy. Both tests involve removing a sample of bone marrow and bone. The samples are sent to a lab for testing.
- Genetic tests to look for gene and chromosome changes
If you are diagnosed with AML, you may have additional tests to see whether the cancer has spread. These include imaging tests and a lumbar puncture, which is a procedure to collect and test cerebrospinal fluid (CSF).
What are the treatments for acute myeloid leukemia (AML)?
Treatments for AML include
- Radiation therapy
- Chemotherapy with stem cell transplant
- Other anticancer medicines
Which treatment you get often depends on which subtype of AML you have. Treatment is usually done in two phases:
- The goal of the first phase is to kill the leukemia cells in the blood and bone marrow. This puts the leukemia into remission. Remission means that the signs and symptoms of cancer are reduced or have disappeared.
- The second phase is known as post-remission therapy. Its goal is to prevent a relapse (return) of the cancer. It involves killing any remaining leukemia cells that may not be active but could begin to regrow.
NIH: National Cancer Institute
[Learn More in MedlinePlus]